Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acurx Pharmaceuticals, Inc.ACXP · Entity 8195 | Chief Financial Officer | April 20, 2026 | April 22, 2026 |
| Enveric Biosciences, Inc.AMRH · Entity 8193 | Director | August 20, 2018 | August 22, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acurx Pharmaceuticals, Inc.
Report date April 20, 2026 · Filed April 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.36 · Expires 2036-04-20 | Direct | 25,900 |
Reported balance
After 2026-04-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-20 · Grant · Acquired 25,900 · Balance 25,900 F1: On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 25,900 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 25,900 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date.
Enveric Biosciences, Inc.
Report date August 20, 2018 · Filed August 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 | Direct | 35,000 |
Reported balance
After 2018-08-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-08-20 · Grant · Acquired 35,000 · Balance 35,000 F1: The options vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders of the Issuer occurring after August 16, 2018. The options will expire on the fifth anniversary of the vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 10,000 |
Reported balance
After 2018-08-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-08-20 · Grant · Acquired 10,000 · Balance 10,000 F2: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F3: The Restricted Stock Units vest on the first anniversary of the grant date. |
| Common StockSEC Table I · non-derivative | Direct | 400 |
Reported balance
Holding disclosure · report date 2018-08-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 400 |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders of the Issuer occurring after August 16, 2018. The options will expire on the fifth anniversary of the vesting date.
F2: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.
F3: The Restricted Stock Units vest on the first anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PLx Pharma Inc.
Report date January 17, 2017 · Filed April 20, 2017
Section 16 reporting ended · disclosed 2017-04-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2027-01-17 | Direct | 130,000 |
Reported balance
After 2017-01-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-17 · Grant · Acquired 130,000 · Balance 130,000 F1: Options to purchase shares of common stock vest as follows: options to purchase 65,000 shares of common stock vested on January 17, 2017; options to purchase 2,708 shares of common stock vest monthly in each of the 23 months after the date of grant and options to purchase 2,716 shares of common stock will vest on the 24th month anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase shares of common stock vest as follows: options to purchase 65,000 shares of common stock vested on January 17, 2017; options to purchase 2,708 shares of common stock vest monthly in each of the 23 months after the date of grant and options to purchase 2,716 shares of common stock will vest on the 24th month anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2026 Filed Apr 22, 2026 16:16 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 25,900 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001104659-26-046833 · tm2612397-1_4seq1.xml · derivative · entry 1 Shawah Robert G. · CIK 0001601121 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,900 Underlying: Common Stock · 25,900 shares Expires 2036-04-20 F1 · derivative.exercise_date: On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 25,900 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 17:47 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 145,500 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001104659-25-010181 · tm255798-3_4seq1.xml · derivative · entry 1 Shawah Robert G. · CIK 0001601121 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,500 Underlying: Common Stock · 145,500 shares Expires 2035-02-05 F1 · derivative.exercise_date: On February 5, 2025, the Reporting Person was granted stock options to purchase 145,500 shares of the Issuer's common stock. These options vest immediately. Read SEC document |
| February 23, 2024 Filed Apr 3, 2024 21:56 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 145,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001104659-24-043292 · tm2411025-3_4seq1.xml · derivative · entry 1 Shawah Robert G. · CIK 0001601121 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2034-02-22 F1 · derivative.exercise_date: On February 23, 2024 (the "Grant Date"), the Reporting Person was granted stock options to purchase 145,000 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person. Read SEC document |
| February 13, 2023 Filed Feb 24, 2023 16:32 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 75,000 | $0.00 Strike: $3.41 | $0.00 |
DisclosureSEC source: 0001104659-23-025335 · tm237745-3_4seq1.xml · derivative · entry 1 Shawah Robert G. · CIK 0001601121 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: On February 13, 2023 (the " Grant Date"), the Reporting Person was granted stock options to purchase 75,000 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 16:06 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 200,000 | $0.00 Strike: $6.18 | $0.00 |
DisclosureSEC source: 0001104659-21-089393 · tm2121425-2_4seq1.xml · derivative · entry 2 Shawah Robert G. · CIK 0001601121 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-06-30 F2 · derivative.exercise_date: On July 1, 2021 (the "Employment Agreement Grant Date"), the Reporting Person was granted stock options to purchase 200,000 shares of the Issuer's common stock in connection with the Reporting Person's service as the Issuer's Chief Financial Officer pursuant to the Reporting Person's employment agreement. 25% of the stock options granted became vested and exercisable on the Employment Agreement Grant Date and 75% of the stock options shall become vested and exercisable as of each monthly anniversary from the Employment Agreement Grant Date, such that all stock options shall be fully vested and exercisable by July 1, 2024. Read SEC document |
| June 29, 2021 Filed Jul 6, 2021 16:06 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 70,000 | $0.00 Strike: $6.26 | $0.00 |
DisclosureSEC source: 0001104659-21-089393 · tm2121425-2_4seq1.xml · derivative · entry 1 Shawah Robert G. · CIK 0001601121 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-06-28 F1 · derivative.exercise_date: On June 29, 2021 (the "June Grant Date"), the Reporting Person was granted stock options to purchase 70,000 shares of the Issuer's common stock. 40% of the stock options granted became vested and exercisable on the June Grant Date and 60% of the stock options shall become vested and exercisable as of each monthly anniversary from the June Grant Date, such that all stock options shall be fully vested and exercisable by June 29, 2024. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:05 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | GrantRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-18-002458 · form410211008swh_08202018.xml · derivative · entry 3 Shawah Robert G. · CIK 0001601121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F3 · derivative.exercise_date: The Restricted Stock Units vest on the first anniversary of the grant date. F3 · derivative.expiration_date: The Restricted Stock Units vest on the first anniversary of the grant date. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:05 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | GrantOption (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0000921895-18-002458 · form410211008swh_08202018.xml · derivative · entry 2 Shawah Robert G. · CIK 0001601121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F1 · derivative.exercise_date: The options vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders of the Issuer occurring after August 16, 2018. The options will expire on the fifth anniversary of the vesting date. F1 · derivative.expiration_date: The options vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders of the Issuer occurring after August 16, 2018. The options will expire on the fifth anniversary of the vesting date. Read SEC document |
| January 17, 2017 Filed Apr 20, 2017 06:31 UTC | PLx Pharma Inc. DPRX · Entity 129056 | GrantOptions · Derivative | 130,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001144204-17-021133 · v464469_4.xml · derivative · entry 1 Shawah Robert G. · CIK 0001601121 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2027-01-17 F1 · derivative.exercise_date: Options to purchase shares of common stock vest as follows: options to purchase 65,000 shares of common stock vested on January 17, 2017; options to purchase 2,708 shares of common stock vest monthly in each of the 23 months after the date of grant and options to purchase 2,716 shares of common stock will vest on the 24th month anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.